Sponsored by
This preclinical study used an interesting combination of immunotherapies (fc-enhanced anti-ctla-4 and anti-pd-1), chemotherapy (doxorubicin), and specialized drug delivery (pulsed ultrasound and microbubbles). It was highly effective in murine models, achieving a 90% cure rate as well as immunological memory. There is a Phase 2 clinical trial at Northwestern University testing this combination in newly diagnosed glioblastoma.